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S U M M A R Y
Objectives: In this systematic literature review we sought to determine whether tattooing is a risk factor
for the transmission of hepatitis C.
Methods: A comprehensive search was performed to identify all case-control, cohort or cross sectional
studies published prior to November 2008 that evaluated risks related to tattooing or risk factors of
transmission of hepatitis C infection.
Results: A total of 124 studies were included in this systematic review, of which 83 were included in the
meta-analysis. The pooled odds ratio (OR) and 95% conﬁdence interval (CI) of the association of tattooing
and hepatitis C from all studies was 2.74 (2.38–3.15). In a subgroup analysis we found the strongest
association between tattooing and risk of hepatitis C for samples derived from non-injection drug users
(OR 5.74, 95% CI 1.98–16.66).
Conclusions: Findings from the current meta-analysis indicate that tattooing is associated with a higher
risk of hepatitis C infection. Because tattooing is more common among the youth and young adults and
hepatitis C is very common in the imprisoned population, prevention programs must focus on
youngsters and prisoners to lower the spread of hepatitis infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Therehasbeenan increase in theglobalprevalenceof tattooing in
recent years. In the USA, 36% of people under 30 have tattoos.1
Studies fromCanada indicate that around8%of high school students
have at least one tattoo,2,3 and among those who did not have a
tattoo, 21% were eager to have one. Tattooing requires injection of
pigments into the dermal layer of skin by puncturing the skin 80 to
150 times a second. Since tattoo instruments come into contactwith
blood and bodily ﬂuids, viral and microbial infections may be
transmitted if the instruments are used on more than one person
without being sterilizedorwithout proper hygiene techniques. Also,
because tattoodyes arenotkept insterile containers theymightplay
a carrier role in transmitting infections. In light of the increase in the
worldwide prevalence of tattoos, it has been postulated that
tattooing may play an important role in the transmission of
blood-borne diseases such as hepatitis B and hepatitis C.
In the USA, approximately 2.3% of adults aged 20 years or older
are positive for anti-hepatitis C virus (HCV) antibody, and between
55%and 84% of these have a chronic infection;4,5 however only 5% to* Corresponding author. Tel.: +1 604 660 6061; fax: +1 604 660 0197.
E-mail address: jane.buxton@bccdc.ca (J. Buxton).
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doi:10.1016/j.ijid.2010.03.01950%of infectedadults are awareof their status.6–8 It is estimated that
210 000 to 275 000 people are currently infectedwith hepatitis C in
Canada, of whom only 30% are aware of their infection.9
Tattooing among prisoners is another issue of importance. The
overall prevalence of hepatitis C among inmates is estimated to be
around 25.2% to 37.4%.10–14 Close to half of inmates may not know
their serostatus, and the rates may vary between men and
women.10–14 Reusing and sharing tattoo needles is reported to be a
common practice among almost 45% of inmates.13 Given that the
annual cost of each new case of hepatitis C for the healthcare
system is estimated at around US$25 000 to US$30 000,15 the
number of new cases of hepatitis that may arise as a result of
tattooing has important clinical as well as public health implica-
tions. Because the results from epidemiological studies regarding
the risk of hepatitis among tattooed individuals are conﬂicting, we
sought to systematically review the literature in order to quantify
the risk of hepatitis in tattooed individuals.
2. Methods
2.1. Search strategy
We identiﬁed relevant studies and abstracts by searching
MEDLINE (1966 to November 2008), EMBASE (1980 to Novemberses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Selection of studies for inclusion in the systematic review and meta-
analysis.
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November 2008), ACP Journal Club (1991 to November 2008),
International Pharmaceutical Abstracts (1970 to November 2008),
BIOSIS Previews (1969 to November 2008),Web of Science (1961 to
November 2008), and Pubmed. Therewas no language restriction in
selecting the studies. The initial search strategywas developed from
theMeSHsubject headings ‘hepatitis’ and ‘tattoo’ inMEDLINE. Titles
were reviewed for relevance from this search, and subject headings
and abstracts were then examined. Appropriate subject headings
and keywordswere added to the search strategy. The scope notes in
MEDLINE and EMBASE were also examined to ensure the correct
subject headingswere used based on their deﬁnitions; other subject
headings were included based on previous indexing and the
inclusion of keywords based on synonyms used in the scope notes.
Consequently, broader MeSH subject headings such as ‘tattooing’,
‘hepatitis’, and ‘hepatitis C’ were included. Proceedings and
conference abstracts were searched through the databases Papers-
First (1993) and ProceedingsFirst (1993) up toOctober 2008. Author
names and year of published work from key papers were entered
into the cited reference search in the Web of Science. We screened
the references of retrieved studies and review articles for any
potentially missed articles. In addition, we hand-searched the
reference lists of retrieved studies as well as journals related to
‘hepatitis’, ‘hepatology’, ‘blood’, ‘infection’, ‘epidemiology’, and
‘gastroenterology’, and abstracts and books related to hepatitis.
We contacted authors to ensure there was no overlap in the sample
included in their studies whenever needed.
2.2. Selection criteria
We considered all observational studies that assessed the
association between tattooing and hepatitis. Observational studies
were included if they (1) clearly deﬁned hepatitis C as either the
primary or secondary outcome; (2) clearly deﬁned tattoos as either
primary or secondary exposure; (3) presented relative risks or odds
ratios and their corresponding conﬁdence intervals or provided
enough data to compute these parameters. In the case of a study
published in different phases or if data froma studywere duplicated
in more than one study, we only included the most recent study.
2.3. Data extraction
We created a spreadsheet and recorded study characteristics
including author names, publication year, country of study, study
design, sample size, study population type, mean age or range,
gender of participants, type of risk factors or confounders adjusted
for, outcome of interest (hepatitis C), and adjusted odds ratio (OR)
and 95% conﬁdence interval (CI). Included articles were reviewed
in full by two independent reviewers (SJ and SB). In studies that
provided several levels of exposure, each exposurewas categorized
and analyzed in the designated subgroup. To assess the quality of
studies we created a quality assessment scale (0 to 9 points) based
on Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) guidelines.16 The scale includes reporting the inclu-
sion/exclusion criteria, outcome deﬁnition, exposure deﬁnition,
risk adjustment, possible sources of confounding, assessment of
data, crude OR (95% CI) report, and adjusted OR (95% CI) report.
2.4. Statistical analysis
We performed several subgroup analyses to investigate the
association between tattooing and hepatitis C among different
populations. We conducted subgroup analyses based on the study
population and study design (case–control, cohort, and cross-
sectional). We also grouped studies into eight main mutually
exclusive subgroups including: community samples, blood donors,hospital samples, injection drug users (IDUs), non-injection drug
users (non-IDUs), drug users, prisoners, and high-risk population
(street youth, HIV patients, tattooed in non-professional shops, and
reused tattoo needles).
For all analyses, we weighted the study-speciﬁc adjusted log
ORs by the inverse of their variances. Both ﬁxed and random effect
models were used to estimate the pooled adjusted OR. Statistical
heterogeneity between studies was evaluated with Cochran’s Q
test and the I2 statistic.17 A sensitivity analysis was carried out to
assess the individual inﬂuence of studies, and the analysis repeated
excluding the studies with the largest weights. We used a funnel
plot18 and Egger’s test19 to assess the presence of publication bias.
Statistical analyses and graphs were performed with RevMan 5
(Review Manager, version 5.0., The Cochrane Collaboration, 2008)
and HEpiMA (Compute Methods Programs Biomed).
3. Results
Figure 1 shows the results of our search strategy and step-by-
step inclusion and exclusion of the retrieved papers. Appendix A
represents the search strategy used in this study. We identiﬁed a[(Figure_1)TD$FIG]
Table 1
Characteristics of studies included in both the systematic review and meta-analysis
Author [Ref.]a Year Location Sample
size
Study
design
Sample derived from Age, years OR/RR 95% CI
1 Alavian 2002 Iran 389 CC Blood donors NR 6.10 2.10–18.30
2 Alizadeh 2005 Iran 427 CS Prison Any age 1.05 0.70–1.60
3 Amiri 2007 Iran 460 CS Prison Mean
(SD) = 34.7 (8.9)
1.80 1.10–3.10
4 Babudieri 2005 Italy 973 CS Prison Mean = 36.9 1.91 1.26–2.92
5 Bair 2005 USA 1002 CS Adolescents in
detention
Range 10–18;
mean = 15
1.90 0.20–1.95
6 Balasekaran 1999 USA 116 CC Hospital Mean (SD) = 44 (11) 5.90 1.10–30.70
7 Bari 2001 Pakistan 57/180 CC Male adults Range 20–70 0.90 0.30–2.70
8 Bollepalli 2007 USA 242 CS HIV patients Range 19–66;
mean
(SD) = 42.3 (9.3)
1.07 0.54–2.09
9 Bra¨u 2002 USA 1016 CS Veterans Range 22–99 2.20 1.30–3.70
10 Branda˜o 2002 Brazil 534 CC Blood donors Range 30–59 4.40 1.60–11.90
11 Briggs 2001 USA 1032 CS Hospital: all
individuals
Range 21–81 2.93 1.70–5.08
People with no
history of IDU
Range 21–81 3.02 1.60–5.66
12 Brillman 2002 USA 121 CC Hospital, emergency
patients
Mean = 43.9 6.30 1.90–24.30
13 Brusaferro 1999 Italy 743 CO Hospital Any age 2.50 1.10–5.60
14 Butler 2007 Australia 612 CS Prison Any age 2.27 1.50–3.44
15 Butler 2004 Australia 90 CS Prison: all Any age 10.80 5.10–16.40
29 CS Prison: IDUs Any age 19.20 8.30–29.80
16 Campello 2002 Italy 2154 CO General population Range 17–67 4.18 1.50–15.22
17 Chang 1999 Taiwan 899 CS Drug users Any age 1.47 0.84–2.56
18 Christensen 2000 Denmark 325 CO Prison Any age 1.60 0.30–7.70
19 Coppola 2007 Italy 3579 CS Healthy subjects Mean (SD) = 33.19
(12.18)
8.56 4.67–15.68
20 Delage 1999 Canada 1335 CC Blood donors Any age 10.3 6.90–15.40
21 Dominguez 2001 Spain 2147 CS Community-based Range 5–70 7.55 2.71–21.02
22 Dominitz 2005 USA 1288 CS Veterans Any age 3.80 2.00–7.10
23 Gates 2004 Australia 25/96 CC Prison Male, mean
(SD) = 29 (7.3);
female, mean
(SD) = 33 (11.5)
1.85 0.80–4.60
24 Goldman 2009 Canada 69/276 CC-M Blood donors Adults 3.47 1.49–8.08
25 Goodrick 1994 England 50/50 CC-M Blood donors: all Range 21–60 20.00 3.10–99.00
Blood donors: non-IDU Range 21–61 20.00 0.90–99.00
26 Gyarmathy 2002 USA 483 CS Community Any age 2.20 1.00–4.70
27 Habib 2000 Egypt 3999 CS Community Any age 0.90 0.30–3.00
28 Hahn 2001 USA 307 CS IDUs Under 30 0.88 0.51–1.52
29 Hajiani 2006 Iran 514 CS Hospital Any age 4.73 1.01–22.10
30 Haley 2001 USA 626 CS Hospital: any tattoo Any age 6.30 3.60–11.20
Hospital: tattooed
at prison
Any age 4.80 0.80–30.10
Hospital: tattooed at
commercial tattoo parlor
Any age 9.30 5.10–16.90
Number of tattoos: 1 Any age 6.30 3.10–12.50
Number of tattoos: 2 Any age 3.20 1.00–10.10
Number of tattoos: 3 Any age 10.20 4.40–23.50
Number of tattoos: >4 Any age 7.50 3.10–18.10
Year tattoo done:
1939–1949 Any age 0.00 0.00
1950–1959 Any age 0.00 0.00
1960–1969 Any age 8.40 3.50–19.90
1970–1979 Any age 7.80 3.80–15.90
1980–1989 Any age 6.30 3.00–13.60
1990–1992 Any age 9.50 2.80–32.20
31 Hammer 2003 USA 981 CO Non-IDUs >18 6.50 0.10–54.00
32 Hand 2005 USA 627 CC Hospital Range 14–99 2.90 1.90–4.60
33 Hellard 2004 Australia 642 CS Prison Mean = 31.6 2.70 1.40–5.20
Any tattoo Mean = 31.6 3.80 2.60–5.50
Professional parlor Mean = 31.6 2.20 1.60–3.20
34 Ho 1997 Taiwan 80 CS Community >7 0.52 0.16–1.62
35 Holsen 1993 Norway 70 CS Prison Range 16–51 5.44 1.68–9.21
36 Howe 2005 USA 740 CS Non-IDUs, tattooed
by friends
Median = 30 3.61 1.15–11.26
Non-IDUs, tattooed
in community
Median = 31 0.65 0.15–2.89
Non-IDUs, tattooed
in prison
Median = 32 1.13 0.36–3.44
37 Hwang 2006 USA 7960 CS Students, all NR 1.11 0.59–2.08
1–2 tattoo 0.76 0.34–1.71
>3 tattoo 2.44 1.04–5.76
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Table 1 (Continued )
Author [Ref.]a Year Location Sample
size
Study
design
Sample derived from Age, years OR/RR 95% CI
Professional tattoo
parlor
0.78 0.36–1.69
Non-professional
tattoo parlor
3.50 1.40–8.82
New or autoclaved
needle
0.64 0.27–1.53
Reused needle 4.90 1.96–12.29
38 Judd 2005 UK 720 CS IDUs Any age 1.13 0.80–1.59
39 Kaldor 1992 Australia 430 CC Blood donors: all Any age 11.00 4.90–26.00
Non-IDUs; no transfusion Any age 27.00 8.40–87.00
40 Kerzman 2007 Israel 256 CC Blood donors;
former Soviet Union
Any age 2.00 0.70–5.50
178 CC Blood donors; native Israeli Any age 1.10 0.10–9.20
41 Kim 2002 Korea 404 CC Community Any age 1.67 0.72–3.93
Kim 2002 Korea 405 CC Hospital Any age 0.88 0.36–2.12
42 Ko 1992 Taiwan 87/122 CC Community-based: all Mean (SD) = 18.7 (0.3) 5.90 1.60–22.0
Single tattoo Mean (SD) = 18.7 (0.3) 5.40 1.40–21.0
Multiple tattoos Mean (SD) = 18.7 (0.3) 8.20 1.50–44.30
Professional tattoo parlor Mean (SD) = 18.7 (0.3) 2.90 0.30–30.10
Non-professional
tattoo parlor
Mean (SD) = 18.7 (0.3) 6.60 1.80–24.90
43 Lai 2007 Taiwan 285 CS Prison Mean (SD) = 34.1 (8.6) 2.97 1.37–6.43
44 Liao 2006 Taiwan 1000 CS Drug users Range 19–65 1.27 0.86–1.89
45 Liao 2006 Taiwan 297 CS Prison Range 16–69 2.24 1.03–4.88
46 Lim 2007 Australia 52 CS IDUs >18 4.18 1.24–14.10
47 Long 2001 Ireland 607 CS Prison; non-IDUs Range 15–73 11.60 1.40–237.30
48 Macı´as 2007 Spain 182 CS Non-IDUs Median = 34 3.50 1.30–9.60
49 Maggi 1999 Italy 2403 CC General population Range 18–85 0.94 0.34–2.60
50 Mariano 2004 Italy 598/7221 CC IDUs and blood
transfusion
Range 15–56 5.60 2.80–11.00
51 Mathei 2005 Belgium 310 CS Drug users Mean (SD) = 33.5 (6.6) 7.99 1.01–63.50
52 Medhat 2002 Egypt 6033 CS Community Any age 1.10 0.50–2.80
53 Mele 1995 Italy 5242 CC Community NR 2.50 0.80–7.79
54 Mu¨ller 2001 Hungary 45 839 CS Blood donors Range 19–74 5.07 2.88–8.93
55 Murphy 2000 USA 758/1039 CC Blood donors Any age 3.90 2.50–6.10
56 Mussi 2007 Brazil 1008 CS HIV patients Mean = 37.2 3.80 2.00–7.00
57 Neal 1994 UK 224 CC Blood donors Mean = 34.6 to 36.6 3.30 1.20–8.70
58 Nguyen 2007 Vietnam 837 CS Community Mean = 42.3 13.37 1.86–96.15
59 Nishioka 2003 Brazil 345 CS Blood donors Range 18–63 6.41 1.29–31.84
60 Nurgalieva 2007 Kazakhstan 290 CS Community Range 10–64 14.4 1.76–118.3
61 Nyamathi 2006 USA 198 CC Homeless IDUs Range 18–65 3.64 1.27–10.37
Homeless non-IDUs Range 18–65 4.51 1.36–14.97
62 O’Brien 2008 Canada 920 CC Blood donors NR 3.80 2.00–7.30
63 Pallas 1999 Spain 1215 CS Prison Mean (SD) = 30.6 (9.9) 3.20 1.40–7.10
64 Parana 1999 Brazil 143 CO Hospital Any age 30.0 3.36–268.11
65 Paris 2003 Thailand 381 CS Community Range 20–45 2.00 0.70–6.00
66 Pourahmad 2007 Iran 1432 CC Prison Range 25–61 2.95 2.34–3.70
67 Richards 2006 Georgia 272 CS Hospital Range 18–74 2.60 1.20–5.70
68 Roy 2001 Canada 437 CO Street youth Mean = 19.5 1.80 0.95–3.60
69 Sahajian 2006 France 988 CS Hospital >18 2.75 1.01–7.51
70 Salleras 1997 Spain 215 CC Pregnant women Mean (SD) = 28.5 (4) 18.15 0.45–759.10
71 Samuel 2001 USA 2898 CO IDUs, tattooed in prison >16 3.40 1.60–7.50
Samuel 2001 USA 2898 CO IDUs, tattooed in
community
>18 1.70 0.90–2.90
72 Sanchez 2000 Peru 2827 CO Blood donors Any age 0.77 0.25–2.25
CO Blood donors Any age 0.65 0.23–1.86
73 Sandhu 1999 Canada 336 CS Hospital; dialysis
patients
Range 18–55;
mean
(SD) = 57.4 (15.4)
3.80 1.00–12.13
74 Shev 1995 Sweden 102 CC Blood donors Range 25–53 9.30 2.44–53.06
75 Shi 2007 Taiwan 1897 CC Military All 20 years old 5.00 1.83–13.65
76 Shopper 1995 USA 500 CS Students Range 14–70 12.19 5.40–28.00
77 Sun 2001 Taiwan 554 CC Community Range 30–64 2.20 0.60–8.10
78 Talamini 2004 Italy 495 CC Hospital Range 18–84 8.49 1.11–67.4
79 Thaikruea 2004 Thailand 495 CC Blood donors >18 1.60 0.96–2.67
80 Utsumi 1995 Japan 201 CC Prison Mean (SD) = 45 (13) 1.57 0.63–3.92
81 Wada 1999 Japan 95 CS Hospital Mean
(SD) = 24.4 (6.1)
5.30 1.79–15.92
82 Watson 1999 Australia 757 CS Community Range 13–50 0.58 0.10–3.30
83 Wolff 2007 Brazil 597 CC Hospital Male, mean
(SD) = 40.3 (8.7);
female, mean
(SD) = 38.9 (9.8)
1.20 0.70–2.10
SD, standard deviation; OR, odds ratio; RR, relative risk; CI, conﬁdence interval; CC, case–control study design; CC-M, case–control matched; CS, cross-sectional study design;
CO, cohort study design; IDU, injection drug user; NR, not reported.
a For references see Appendix 2.
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S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940e932total of 1299 citations related to risk factors of hepatitis. A total of
272 studies were excluded as duplicates, 717 studies were
excluded after reviewing titles, 170 excluded after reviewing
abstracts, and 16were excluded after reviewing the full text. A ﬁnal
number of 124 papers from 30 countries that reported an
association between tattooing and the risk of transmission of
hepatitis C were included in this systematic review (Appendix B).
Characteristics of the 83 studies (45 cross-sectional, 30 case–
control, and eight cohort) with a total of 132 145 participants that
were included in the meta-analysis are represented in Table 1.Table 2
Characteristics of studies included in the systematic review only
Author [Ref.]a Year Country Sample size Study
design
Sa
fr
Abildgaard 1991 Denmark 1 CR H
Bourliere 2002 France 1183 CS H
Brind 1996 UK 25 CS El
Champion 2004 UK 362 CO Pr
Chen 1995 Taiwan 114 CS H
Cheung 2000 USA 8558 CS Ve
Cunha 2007 Mozambique 1578 CS Bl
Dalgard 2002 Norway 116 CS H
Deterding 2008 Spain 30 CS H
Dietemann-Molard 1991 France 1 CR H
Ford 2000 Canada 520 CS Pr
Fox 2005 USA 469 CS Pr
Hajiani 2008 Iran 1264 CS H
Haley 2003 USA 626 CS H
Kumar 2005 India 1900 CS H
Lifson 2001 USA 201 CS H
Limentani 1979 USA 34 CR H
Luksamijarulkul 1997 Thailand 200 CS Fe
w
Luksamijarulkul 1996 Thailand 150 CS ID
Martin 1992 USA 538 CC Bl
Meyer 1991 USA 50 CS H
Michault 2000 France 1455 CS H
pr
Miller 2009 Australia 662 CS Pr
Murray 2003 USA 305 CS Pr
Nishioka 2002 Brazil NR CS TT
Pallas 1999 Spain 779 CS Pr
Patino-Sarcinelli 1993 Brazil 1239 CC Bl
Polizzotto 2008 Australia 1449 CS Bl
Post 2001 Australia 1 CR Pr
Poulin 2007 Canada 1607 CS Pr
Robotin 2004 Australia 912 CS H
Sayad 2008 Iran 1721 CS Re
Silverman 2000 USA 212 CC Em
ou
Stein 2004 USA 198 CS H
Sypsa 2001 Greece 6047 CS Em
17
Tanwandee 2006 Thailand 1329 CC Bl
Thompson 1996 Australia 1 CR Pr
Vaziri 2008 Iran 888 CS H
Vescio 2008 Italy NR NR Pr
Yee 2001 USA 148 CR H
Zeuzem 1996 Germany 160 CS H
ca
CR, case report; CS, cross-sectional; CO, cohort; CC, case–control; SD, standard deviation
HCV, hepatitis C virus; HBV, hepatitis B virus.
a For references see Appendix 2.A total of 41 studieswere not included in themeta-analysis. The
reasons for not including these studies in the meta-analysis are
explained in Table 2.
3.1. Tattoo and hepatitis
Results of the current meta-analysis indicate a strong associa-
tion between tattooing and the risk of hepatitis C when all studies
are combined (pooled OR 2.24, 95% CI 2.01–2.50). In a subgroup
analysis we found the strongest association between tattooing andmple derived
om
Age, years Reason for exclusion
from meta-analysis
ospital Mean = 40 Case report
ospital Mean (SD) = 41.1 (12.7) Tattoo data for
genotype study
derly patients >65 Not enough data
ison >21 Not enough data
ospital Mean (SD) = 49 (15) Not enough data
terans Range 28–89, mean 48.4 Not enough data
ood donors Range 15–49 Combined data on
tattoo/scariﬁcation
ospital Median: IDU = 32;
non-IDU = 35
Not enough data; three
documented cases of
hepatitis C with tattooing
ospital Older than 30 Not enough data
ospital Mean = 40 Case report
ison Any ages Not enough data
ison Any ages Combined data on tattoo
and piercing
ospital Range 8–72 Not enough data
ospital All ages Duplicate
ospital Range 15–39 Combined data on
acupuncture and tattoo
omeless Range 15–22 Not enough data
ospital Range 16–28 Case series
male sex
orkers
NR Paper could not retrieved
Us NR Paper could not retrieved
ood donors Mean = 36.8 Combined data for tattoo
and IDU
ospital Range 20–83 Not enough data
ospital,
egnant women
NR Combined data on tattoo
and piercing
ison >18 Not enough data
ison Youth Not enough data
D NR Data on TTD not HCV/HBV
ison Mean (SD) = 27.2 (5.4) Hepatitis B and hepatitis
C co-infection data
ood donors Range 18–64 Not enough data
ood donors Any ages Data on TTD not HCV/HBV
ison Mean = 25 Case report
ison Mean: female = 35.5;
male = 33.3
Combined data on HIV–HCV
ospital Any ages Not enough data
sidents Any ages Not enough data
ergency
t-patient
Range 18–55 Not enough data
omeless Range 18–65 Not enough data
ployees of
companies
Range 15–70;
mean (SD) = 40 (10.1)
Not enough data
ood donors Mean = 34 Combined data on tattoo
and piercing
ison Mean = 39 Case report
ospital Mean (SD) = 30.7 (7.6) Data are not presented
appropriately
ison NR Meta-analysis
ospital Range 18–72 Not enough data
ospital hepatitis
ses
NR Not enough data
; NR, not reported; IDU, injection drug user; TTD, transfusion transmitted disease;
[(Figure_3)TD$FIG]S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940 e933the risk of hepatitis C for samples derived from non-IDUs (OR 5.74,
95% CI 1.98–16.66), followed by blood donors (OR 3.73, 95% CI
2.46–5.67), hospital samples (OR 3.20, 95% CI 2.25–4.56), IDUs (OR
3.06, 95% CI 1.29–7.25), high-risk populations (OR 2.80, 95% CI
1.63–4.82), community samples (OR 2.79, 95% CI 1.95–4.00),
prison samples (OR 2.56, 95% CI 1.97–3.32), and drug users (OR
1.46, 95% CI 0.93–2.30) (Figures 2 and 3).
We conducted a subgroup analysis to investigate the effect of
the country where the study had been conducted, study design,
and professional parlor vs. non-professional parlor on the
transmission of hepatitis C. We combined data from community
samples, blood donors, and hospital samples in a single group
(group 1) and data from IDUs, non-IDUs, drug users (any),
prisoners, and high-risk populations in a second group (group 2)
(Table 3). The association between tattooing and hepatitis C
was the strongest in group 2 studies in Australia (OR 5.90, 95% CI
2.62–13.30), followed by group 1 studies in Iran (OR 5.61, 95% CI
2.31–13.62) and Canada (OR 5.15, 95% CI 2.65–9.98). The
association between tattooing and hepatitis C was the strongest
[(Figure_2)TD$FIG]
Figure 2. Tattooing and the risk of hepatitis C among the community samples, blood
donors, and hospital samples.
Figure 3.among case–control studies, followed by cross-sectional and
cohort studies (Table 3). Also, the association between tattooing
and hepatitis C was signiﬁcant for tattoos done in non-professional
parlors or done by friends (OR 2.80, 95% CI 1.29–6.08).
We conducted a sensitivity analysis to review the effects of 11
studies with wide conﬁdence intervals (References W37, W45,
W53, W64, W71, W82, W85, W90, W101, W106, W113;
Appendix B) on the pooled OR (95% CI). The analysis was
conducted multiple times; ﬁrst all 11 studies were removed from
the analysis, and then one study was removed from the analysis at
a time. We did not ﬁnd a signiﬁcant difference between pre- and
post-sensitivity OR (95% CI) when all 11 studies were removed
from the analysis (OR 2.12, 95% CI 1.91–2.36). We also found no
signiﬁcant difference between the pooled pre-sensitivity effect
size (OR 2.74, 95% CI 2.38–3.15) and post-sensitivity effect size
after removing any of these studies – Ref. W37, OR 2.22, 95% CI
2.00–2.48; Ref. W45, OR 2.24, 95% CI 2.01–2.49; Ref. W53, OR 2.21,
95% CI 1.98–2.46; Ref. W64, OR 2.24, 95% CI 2.01–2.50; Ref. W71,
OR 2.24, 95% CI 2.01–2.49; Ref. W82, OR 2.23, 95% CI 2.00–2.49;
Ref. W85, OR 2.23, 95% CI 2.00–2.49; W90, OR 2.23, 95% CI 2.00–
2.48; Ref. W101, OR 2.24, 95% CI 2.01–2.50; Ref. W106, OR 2.24,
95% CI 2.01–2.50; and Ref. W113, OR 2.23, 95% CI 2.01–2.49, from
the analysis (for references see Appendix B).
Table 3
Subgroup analysis for association between tattooing and hepatitis C
Number of
OR/RR included
Subgroupa Pooled OR
(random effect)
95% CI
Country
Australia 4 BD, H, C 3.30 1.63–6.69
7 IDU, non-IDU, DU, P, HR 5.90 2.62–13.30
Brazil 4 BD, H, C 4.30 1.25–14.73
1 Not enough studies (IDU, non-IDU, DU, P, HR) - -
Canada 4 BD, H, C 5.15 2.65–9.98
1 Not enough studies (IDU, non-IDU, DU, P, HR) - -
Iran 2 BD, H, C 5.61 2.31–13.62
3 IDU, non-IDU, DU, P, HR 1.80 0.91–3.56
Italy 6 BD, H, C 3.32 1.56–7.09
2 IDU, non-IDU, DU, P, HR 3.16 1.10–9.06
Taiwan 4 BD, H, C 2.40 0.78–7.36
5 IDU, non-IDU, DU, P, HR 1.97 1.26–3.10
USA 13 BD, H, C 3.38 2.27–5.02
14 IDU, non-IDU, DU, P, HR 2.10 1.75–2.51
Study design
33 Case–control studies 3.25 2.50–4.22
10 Cohort studies 2.07 1.31–3.27
49 Cross-sectional studies 2.83 2.32–3.45
Hepatitis C with tattoo place
Professional parlors 4 1.28 0.68–2.39
Non-professional parlors/friend 4 2.80 1.29–6.08
OR, odds ratio; RR, relative risk; CI, conﬁdence interval.
a Group 1: BD, blood donor sample; H, hospital sample; C, community sample. Group 2: IDU, sample from injection drug users; non-IDU, sample from non-injection drug
users; DU, sample from drug users; P, sample from prison; HR, sample from high-risk population.
Table 4
Pre- and post-sensitivity analysis for I2 test of heterogeneity
Pre-sensitivity Post-sensitivity
No. of ORs OR (95%CI) I2 No. of ORs OR (95%CI) I2 Studies that were the source of heterogeneitya
Community samples 24 2.79 (1.95–4.00) 75% 13 3.42 (2.67–4.37) 10% W: 8, 25, 39, 43, 48, 51, 55, 68, 72, 108, 121
Blood donors 17 3.73 (2.46–5.67) 77% 12 4.32 (3.42–5.47) 0 W: 28, 37, 103, 115
Hospital samples 16 3.20 (2.25–4.56) 56% 14 3.68 (2.91–4.67) 0 W: 55, 122
Prison samples 19 2.56 (1.97–3.32) 84% 15 1.90 (1.85–1.95) 0 W: 3, 17, 49, 96
IDUs 8 3.06 (1.29–7.25) 94% 4 3.98 (2.67–5.93) 0 W: 17, 40, 52, 102
Non-IDUs 6 5.74 (1.98–16.66) 73% 3 4.13 (2.00–8.42) 0 W: 37, 50, 53
Drug users 3 1.46 (0.93–2.30) 33% 2 1.34 (0.97–1.84) 0 W71
High-risk samples 6 2.80 (1.63–4.82) 63% 4 4.17 (2.73–6.36) 0 W: 9, 99
OR, odds ratio; CI, conﬁdence interval; IDU, injection drug user.
a For references see Appendix 2.
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940e934We examined the heterogeneity by excluding studies that did
not report adjusted OR/relative risk (RR) from the analysis. Post-
sensitivity pooled OR and I2 of heterogeneity did not change
signiﬁcantly (pre-sensitivity OR 2.74, 95% CI 2.38–3.15, I2 = 81%;
post-sensitivity OR 2.41, 95% CI 1.86–3.14, I2 = 75%). We also
examined the source of heterogeneity in all subgroups and
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Figure 4. Funnel plot for publication bias.attempted to identify the studies that introduced heterogeneity
and their effect on the pooled OR (95% CI). Table 4 presents the pre-
and post-sensitivity pooled OR (95% CI) and the studies that were
identiﬁed as a source of heterogeneity. As represented in Table 4, I2
of heterogeneity improved to a non-signiﬁcant level in all
subgroups, however the pooled OR (95% CI) did not change
signiﬁcantly.
We scored all the studies based on a 0–9 scale developed from
MOOSE guidelines.16 The mean score from all the studies was 7
with a range of 6 to 9. We found no association between study
quality scores and the pooledmeasure of effect. However, results of
our assessment indicate there is a possibility of publication bias for
the outcome hepatitis C for studies of small effect size showing
negative results (Figure 4). We believe that this is unlikely to
change the overall results, since the majority of included studies
were of high quality and precision. However this should be
interpreted with caution in the face of heterogeneity in studies.
4. Discussion
Results of our systematic review indicate an increase in the risk
of hepatitis C infection among those who have tattooed. The
strength of our review is mainly in the large number of studies and
multinational nature of the study participants. In light of the
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940 e935observational nature of the studies in this review, the association
between tattooing and hepatitis was strong in all subgroups and
consistent across all study designs. We believe that having a tattoo
is a strong risk factor for transmission of hepatitis C for two
reasons. First, several studies have reported an association
between tattooing and other infections including HIV,20 hepatitis
B,21 leprosy,22 and methicillin-resistant Staphylococcus aureus.23
Secondly, some studies have shown that the risk of hepatitis
infection increases with the increase in the surface area covered by
a tattoo, as well as the number of tattoos received by an individual.
For example, a study found that the RR (95% CI) for the association
between tattooing and risk of hepatitis C for tattoos that covered a
surface area of 1–4 cm2 was 5.0 (2.6–9.6), whereas the RR for
tattoos that covered an area of 20 cm2 was 12.2 (4.6–32.2) (Ref.
W98, Appendix B). Also, the incidence of hepatitis C after tattooing
has been shown to have a direct association with the number of
tattoo experiences (Ref. W44, Appendix B).
HCV has become the most common chronic blood-borne
infection in the USA and the leading indication for liver transplan-
tation.24 Given that hepatitis C can spread through percutane-
ous25,26 or mucous membrane exposure to blood,27 needle-stick
injury,28 and tattooing using non-sterile equipment,29 several
measures should be implemented to prevent the transmission of
hepatitis C among tattoo recipients. First, education programs for
tattoo artists must be implemented to stress the importance of
proper hygiene, as well as the potential for spread of blood-borne
infectionsby tattooneedles. Second, parlor owners and tattoo artists
should be required to keep records of their clients, to inform tattoo
recipients about possible risks related to tattooing, and to report any
adverse event related to tattooing to the health authorities. Third,
because most tattoo recipients are young adults, education efforts
should focus on this age group to promote tattoo-related risk
awareness. When seeking tattooing services, clients should be
advised to be alert to the use of equipment that has not been
adequately sterilized or disinfected. HCV and other blood-borne
pathogens can be transmitted if tools are not sterile or if the tattoo
artist does not follow proper infection-control procedures (e.g.,
washing hands, using latex gloves, and cleaning and disinfecting
surfaces and instruments). Fourth, clinicians should consider
screening for hepatitis C among those who have recently received
tattoos or have a history of receiving a tattoo. And last, current
tattooing regulations and policies need to be updated to enforce
infection control measures among tattoo artists.
The risk from tattooing may depend on the background
prevalence of hepatitis C in the population. For instance, our
results indicate that the OR/RR for the association between
tattooing in prison and the risk of transmission of hepatitis C is
lower compared to that from community samples. However,
results of prior research indicate that the prevalence of hepatitis C
among inmates in some countries is more than 20 times higher
than that in the general population, which indicates that tattooing
in prison presents a higher risk compared to tattooing outside
prison.30We calculated the population attributable fraction for the
association between tattooing and the risk of hepatitis C for tattoos
done in prison and out of prison based on a tattooing prevalence of
11% to 27%14 among inmates and 8% in the general population.2,3
Results indicate that in countries with data close to these
assumptions, 12% to 25% of hepatitis C infections in prison and
6% of the hepatitis C infections in the community are related to
tattooing. These ﬁndings indicate that there is a clear need for
establishing comprehensive programs that provide safer tattooing
practices in prisons. One such program was initiated in Canada in
2006, but the program was terminated before the potential
beneﬁts could be evaluated. Similar programs may be able to
prevent not only the transmission of hepatitis C, but also the
transmission of other blood-borne infections.Our study is subject to several limitations, mainly because of
the observational nature of the studies included in the review.
First, although some studies were published relatively recently,
information on the history of tattooing was taken in the past,
which may not reﬂect the current population risk of hepatitis
infection. Second, publication bias in this study indicates a lack of
publication of some studies with non-signiﬁcant effects, which
may amplify the OR/RR towards a higher association. However the
association between tattooing and risk of transmission of hepatitis
C was so strong in seven out of eight subgroups that this leaves no
place for doubt in considering tattooing as an important risk factor
in the transmission of hepatitis C. To lower the spread of hepatitis
infection, prevention programsmust focus on the youth and young
adults, the populationsmost likely to get tattoos, and prisoners, the
population that faces the higher prevalence of hepatitis C.
Conﬂict of interest: None of the authors in this study have any
conﬂict of interest in the tattoo industry. There was no source of
funding for this study.
Appendix A. Search strategy
(1) MEDLINE (1966 to most recent) using the optimally sensitive
strategy developed for the identiﬁcation of relevant papers
1 exp Tattooing/
2 tattoo$.tw.
3 body art.tw.
4 piercing.tw.
5 or/1-4
6 exp hepatitis/
7 exp hepatitis C/
8 jaundice.pt.
9 or/6-8
10 and/5,9
11 exp case-control studies/
12 exp cross-Sectional Studies/
13 exp cohort studies/
14 exp case report/
15 exp risk factors/
16 case control.pt.
17 cohort.pt.
18 cross sectional.pt.
19 population based.pt.
20 matched case control.pt.
21 systematic review/
22 meta-analysis/
23 case report.pt.
24 case series.pt
25 or/11-24
26 and/10,25
(2) EMBASE (1980 to most recent)
1. exp tattooing/
2. tattoo$.tw.
3. body art.t.w.
4. ear piercing.tw.
5. piercing.tw.
6. body piercing.tw.
7. or/1,6
8. exp hepatitis C/
9. exp hepatitis/
10. jaundice.ab.
11. or/8,10
12. exp case-control studies/
13. exp cross-Sectional Studies/
14. exp cohort studies/
15. exp case report/
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940e93616. risk factors.tw.
17. exp Meta analysis/
18. ((meta adj analy$) or meta-analysis$).tw.
19. (systematic adj (review$1 or overview$1)).tw.
20. liverlit.ab.
21. bloodlit.ab.
22. bibligraph$.ab.
23. hand-search$.ab.
24. manual search$.ab.
25. relevant journals.ab.
26. or/12,25
27. and/7,11,26
(3) We hand searched the following journals using keywords such,
tattooing, risk factors of hepatitis B/C, correlates of hepatitis B/
C, and hepatitis non-A non-B
 American Journal of Epidemiology
 Blood
 Canadian Journal of Public Health
 Canadian Medical Association Journal
 Current Hepatitis Reports
 Epidemiology: The International Society for Epidemiology
 European Journal of Epidemiology
 Gastroenterology
 Gastroenterology journals
 Hematology
 Hepatitis
 Hepatitis Foundation
 Hepatitis Monthly
 Hepatology
 Hepatology Research
 Infectious disease
 Infectious Diseases Society of America
 Journal of Hepatology
 Journal of Viral Hepatitis
 Journal of Virology
 Liver
 Liver International
 Medical virology
 National Institutes of Health (NIH)
(4) Searched for gray literature in Google and Google scholars for:
abstracts, full papers, power point presentations, organiza-
tional publications, and abstracts of conferences related to risk
factors of transmission of hepatitis, hepatitis C, and hepatitis
non-A non-B.
Appendix B. List of papers included in the systematic review.
W1. Abildgaard N, Peterslund NA. Hepatitis C virus transmitted
by tattooing needle. Lancet 1991;338:460.
W2. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors
in Iranian volunteer blood donors: a case–control study. J
Gastroenterol Hepatol 2002;17:1092–7.
W3. Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of
hepatitis C virus infection and its related risk factors in drug
abuser prisoners in Hamedan, Iran. World J Gastroenterol
2005;11:4085–9.
W4. Amiri ZM, Rezvani M, Shakib RJ, Shakib AJ. Prevalence of
hepatitis C virus infection and risk factors of drug using
prisoners in Guilan province. Eastern Mediterr Health J
2007;13:250–6.
W5. Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B,
et al. Correlates of HIV, HBV, and HCV infections in a prison
inmate population: results from a multicentre study in
Italy. J Med Virol 2005;76:311–7.W6. Bair RM, Baillargeon JG, Kelly PJ, Lerand SJ, Williams JF,
Lyerla R, Alter MJ. Prevalence and risk factors for hepatitis C
virus infection among adolescents in detention. Arch
Pediatr Adolesc Med 2005;159:1015–8.
W7. Balasekaran R, Bulterys M, Jamal MM, Quinn PG, Johnston
DE, Skipper B, et al. A case–control study of risk factors for
sporadic hepatitis C virus infection in the southwestern
United States. Am J Gastroenterol 1999;94:1341–6.
W8. Bari A, Akhtar S, Rahbar MH, Luby SP. Risk factors for
hepatitis C virus infection in male adults in Rawalpindi-
Islamabad, Pakistan. Trop Med Int Health 2001;6:732–8.
W9. Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, Van Thiel
DH, Nadir A. Prevalence of risk factors for hepatitis C virus
in HIV-infected and HIV/hepatitis C virus-coinfected
patients. Sex Transm Dis 2007;34:367–70.
W10. Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I,
Lecomte L, et al. Epidemiological changes in hepatitis C
virus genotypes in France: evidence in intravenous drug
users. J Viral Hepat 2002;9:62–70.
W11. Bra¨u N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, et al.
Prevalence of Hepatitis C and coinfection with HIV among
United States veterans in the New York City metropolitan
area. Am J Gastroenterol 2002;97:2071–8.
W12. Branda˜o AB, Fuchs SC. Risk factors for hepatitis C virus
infection among blood donors in southern Brazil: a case–
control study. BMC Gastroenterol 2002;2:18. This article
is available from: http://www.biomedcentral.com/1471-
230X/2/18.
W13. BriggsME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N,
Wright TL. Prevalence and Risk factors for hepatitis C virus
infection at an urban veterans administration medical
center. Hepatology 2001;34:1200–5.
W14. Brillman JC, Crandall CS, Florence CS, Jacobs JL. Prevalence
and risk factors associated with hepatitis C in ED patients.
Am J Emerg Med 2002;20:476–80.
W15. Brind AM, Watson JP, James OF, Bassendine MF. Hepatitis C
virus infection in the elderly. Q J Med 1996;89:291–6.
W16. Brusaferro S, Barbone F, Andrian P, Brianti G, Ciccone L,
Furlan A, et al. A study on the role of the family and other
risk factors in HCV transmission. Eur J Epidemiol 1999;15:
125–32.
W17. Butler T, Kariminia A, Levy M, Kaldor J. Prisoners are at risk
for hepatitis C transmission. Eur J Epidemiol 2004;19:
1119–22.
W18. Butler T, Boonwaat L, Hailstone S, Falconer T, Lems P, Ginley
T, et al. The 2004 Australian prison entrants’ blood-borne
virus and risk behaviour survey. Aust N Z J Public Health
2007;31:44–50.
W19. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seropreva-
lence, viremia and genotype distribution of hepatitis C
virus: a community-based population study in northern
Italy. Infection 2002;30:7–12.
W20. Champion JK, Taylor A, Hutchinson S, Cameron S, McMe-
namin J, Mitchel A, Goldberg D. Incidence of hepatitis C
virus infection and associated risk factors among Scottish
prison inmates: a cohort study. Am J Epidemiol 2004;159:
514–9.
W21. Chang CJ, Lin CH, Lee CT, Chang SJ, Ko YC, Liu HW. Hepatitis
C virus infection among short-term intravenous drug users
in southern Taiwan. Eur J Epidemiol 1999;15:597–601.
W22. Chen TZ,Wu JC, Yen FS, ShengWY, Hwang SJ, Huo TI, Lee SD.
Injectionwith nondisposable needles as an important route
for transmission of acute community-acquired hepatitis C
infection in Taiwan. J Med Virol 1995;46:247–51.
W23. Cheung RC. Epidemiology of hepatitis C virus infection in
American veterans. Am J Gastroenterol 2000;95:740–7.
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940 e937W24. Christensen PB, Krarup HB, Niesters HGM, Norder H,
Georgsen J. Prevalence and incidence of bloodborne viral
infections among Danish prisoners. Eur J Epidemiol
2000;16: 1043–9.
W25. Coppola RC, Masia G, Pradat P, Trepo` C, Carboni G, Argiolas
F, Rizzetto M. Impact of hepatitis C virus infection on
healthy subjects on an Italian island. J Viral Hepat 2000;7:
130–7.
W26. Cunha L, Plouzeau C, Ingrand P, Gudo JPS, Ingrand I,
Mondlane J, et al. Use of replacement blood donors to study
the epidemiology of major blood-borne viruses in the
general population of Maputo, Mozambique. J Med Virol
2007;79:1832–40.
W27. Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard
B, Bell H; Construct Group. Treatment of chronic hepatitis C
in injecting drug users: 5 years’ follow-up. Eur Addict Res
2002;8:45–9.
W28. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, David
PI, Fast M. Risk factors for acquisition of hepatitis C virus
infection in blood donors: results of a case–control study.
Gastroenterology 1999;116:893–9.
W29. Deterding K, Wiegand J, Gru¨ner N, Wedemeyer H. Medical
procedures as a risk factor for HCV infection in developed
countries: do we neglect a signiﬁcant problem in medical
care? J Hepatol 2008;48:1018–21.
W30. Dietemann-Molard A, Braun JJ, Sohier B, Pauli G. Hepatitis C
virus transmitted by tattooing needle. Lancet 1991;338:60.
W31. Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L.
Community-based seroepidemiological survey of HCV
infection in Catalonia, Spain. J Med Virol 2001;65:688–93.
W32. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C,
Sporleder JL, VA Cooperative Study Group 488. Elevated
prevalence of hepatitis C infection in users of United States
veterans medical centers. Hepatology 2005;41:88–96.
W33. Ford PM, Pearson M, Sankar-Mistry P, Stevenson T, Bell D,
Austin J. HIV, hepatitis C and risk behaviour in a Canadian
medium security Federal penitentiary. Q J Med 2000;93:
113–9.
W34. Fox RK, Currie SL, Evans J,Wright TL, Tobler L, Phelps B, et al.
Hepatitis C virus infection among prisoners in the California
state correctional system. Clin Infect Dis 2005;41:177–86.
W35. Gates JA, Post JJ, Kaldor JM, Pan Y, Haber PS, Lloyd AR, et al.
Risk factors for hepatitis C infection and perception of
antibody status amongmale prison inmates in theHepatitis
C Incidence and Transmission in Prisons Study cohort,
Australia. J Urban Health 2004;81:448–52.
W36. GoldmanM, Xi G, Yi QL, FanW, O’Brien SF. Reassessment of
deferrals for tattooing and piercing. Transfusion 2009;49:
648–54.
W37. Goodrick MJ, Gray SF, Rouse AM, Waters AJ, Anderson NA.
Hepatitis C (HCV)-positive blood donors in southwest
England: a case control study. Transfus Med 1994;4:113–9.
W38. Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des
Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus,
and hepatitis C virus infections among non-injecting heroin
users. J Acquir Immune Deﬁc Syndr 2002;30:448–56.
W39. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel
Hamid M, Gamil F, et al. Hepatitis C virus infection in a
community in the Nile Delta: risk factors for seropositivity.
Hepatology 2001;33:248–53.
W40. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K,Moss AR. Hepatitis
C virus infection and needle exchange use among young
injection drug users in San Francisco. Hepatology
2001;34:180–7.
W41. Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E,
Rajabi T. Seroepidemiology of hepatitis C and its risk factorsin Khuzestan Province, south-west of Iran: a case–control
study. World J Gastroenterol 2006;12:4884–7.
W42. Hajiani E, Hashemi SJ, Masjedizadeh AR. Seroepidemiology
of hepatitis B virus infection in Khuzestan Province,
southwest of Iran. Hepatitis Monthly 2008;99:34–8.
W43. Haley RW, Fischer RP. The tattooing paradox. Are studies of
acute hepatitis adequate to identify routes of transmission
of subclinical hepatitis C infection? Arch Intern Med
2003;163:1095–8.
W44. Haley RW, Fischer RP. Commercial tattooing as a poten-
tially important source of hepatitis C infection clinical
epidemiology of 626 consecutive patients unaware of their
hepatitis C serologic status.Medicine (Baltimore) 2001;80:
134–51.
W45. Hammer GP, Kellogg TA, McFarland WC, Wonge, Louie B,
Williams I, et al. Low incidence and prevalence of hepatitis
C virus infection among sexually active non-intravenous
drug-using adults, San Francisco, 1997–2000. Sex Transm
Dis 2003;30:919–24.
W46. Hand WL, Vasquez Y. Risk factors for hepatitis C on the
Texas–Mexico border. Am J Gastroenterol 2005;100:
2180–5.
W47. Hellard ME, Hocking JS, Crofts N. The prevalence and the
risk behaviours associated with the transmission of
hepatitis C virus in Australian correctional facilities.
Epidemiol Infect 2004;132:409–15.
W48. Ho MS, Hsu CP, Yuh Y, King CC, Tsai JF, Mau YC, et al. High
rate of hepatitis C virus infection in an isolated community:
persistent hyperendemicity or period-related phenomena?
J Med Virol 1997;52:370–6.
W49. Holsen DS, Harthug S, MyrmeH. Prevalence of antibodies to
hepatitis C virus and association with intravenous drug
abuse and tattooing in a national prison in Norway. Eur J
Clin Microbiol Infect Dis 1993;12:673–6.
W50. Howe CJ, Fuller CM, OmpadDC, Galea S, Koblin B, Thomas D,
Vlahov D. Association of sex, hygiene and drug equipment
sharing with hepatitis C virus infection among non-
injecting drug users in New York City. Drug Alcohol Depend
2005;79:389–95.
W51. Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R,
Alter MJ. Relationship of cosmetic procedures and drug use
to hepatitis C and hepatitis B virus infections in a low-risk
population. Hepatology 2006;44:341–51.
W52. Judd A, Hutchinson S,Wadd S, HickmanM, Taylor A, Jones S,
et al. Prevalence of, and risk factors for, hepatitis C virus
infection among recent initiates to injecting in London and
Glasgow: cross sectional analysis. J Viral Hepat 2005;12:
655–62.
W53. Kaldor JM, Archer GT, BuringML, Ismay SL, Kenrick KG, Lien
AS, et al. Risk factors of hepatitis C infection in blood
donors: a case–control study.Med J Aust 1992;157:227–30.
W54. Kerzman H, Green MS, Shinar E. Risk factors for hepatitis C
virus infection among blood donors in Israel: a case–control
study between native Israelis and immigrants from the
former Soviet Union. Transfusion 2007;47:1189–96.
W55. Kim YS, Ahn YO, Lee HS. Risk factors for hepatitis C virus
infection among Koreans according to the hepatitis C virus
genotype. J Korean Med Sci 2002;17:187–92.
W56. Ko YC, HoMS, Chiang TA, Chang SJ, Chang PY. Tattooing as a
risk of hepatitis C infection. J Med Virol 1992;38:288–91.
W57. Kumar A, Sharma KA, Gupta RK, Kar P, Murthy NS. Hepatitis
C virus infection during pregnancy in North India. Int J
Gynecol Obstet 2005;88:55–6.
W58. Lai SW, Chang WL, Peng CY, Liao KF. Viral hepatitis among
male amphetamine-inhaling abusers. Int Med J 2007;37:
472–7.
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940e938W59. Liao KF, Lai SW, Chang WL, Hsu NY. Screening for viral
hepatitis among male non-drug-abuse prisoners. Scand J
Gastroenterol 2006;41:969–73.
W60. Liao KF, Peng CY, Lai SW, Chang WL, Hsu NY. Descriptive
epidemiology of hepatitis C virus among male heroin
abusers in Taiwan. South Med J 2006;99:348–51.
W61. Lifson AR, Halcon LL. Substance abuse and high risk needle-
related behaviour among homeless youth in Minneapolis:
implications for prevention. J Urban Health 2001;78:690–8.
W62. Lim MS, Sundaram K, Aitken CK, Hellard ME. Blood-borne
viruses and risk behaviours among injecting drug users
recruited from needle and syringe programs in Victoria’s
Eastern Metropolitan Region. Aust J Primary Health
2007;13:69–76.
W63. Limentani AE, Elliott LM, NoahND, Lamborn JK. An outbreak
of hepatitis B from tattooing. Lancet 1979;2:86–8.
W64. Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley
F, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis
C, and HIV and risk factors in entrants to Irish prisons: a
national cross sectional survey. BMJ 2001;323:1209–13.
W65. Luksamijarulkul P, Deangbubpha A. Hepatitis C antibody
prevalence and risk factors of some female sex workers in
Thailand. Southeast Asian J Trop Med Public Health
1997;28:507–12.
W66. Luksamijarulkul P, Plucktaweesak S. High hepatitis C
seroprevalence in Thai intravenous drug abusers and
qualitative risk analysis. Southeast Asian J Trop Med Public
Health 1996;27:654–8.
W67. Macı´as J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA,
et al. High prevalence of hepatitis C virus infection among
noninjecting drug users: association with sharing the
inhalation implements of crack. Liver Int 2008;28:781–6.
W68. Maggi G, Armitano S, Brambilla L, Brenna M, Cairo M,
Galvani G, et al. Hepatitis C infection in an Italian
population not selected for risk factors. Liver 1999;19:
427–31.
W69. Mariano A, Mele A, Tosti ME, Parlato A, Gallo G, Ragni P,
et al.; SEIEVA Collaborating Group. Role of beauty
treatment in the spread of parenterally transmitted
hepatitis viruses in Italy. J Med Virol 2004;74:216–20.
W70. Martin P. Hepatitis C: evaluating the seropositive blood
donor. Hepatology 1992;15:967–9.
W71. Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G,
Van Damme P, Buntinx P. Molecular epidemiology of
hepatitis C among drug users in Flanders, Belgium:
association of genotype with clinical parameters and with
sex- and drug-related risk behaviours. Eur J Clin Microbiol
Infect Dis 2005;24:514–22.
W72. Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L,
Nafeh M, et al. Hepatitis C in a community in upper Egypt:
risk factors for infection. Am J Trop Med Hyg 2002;66:
633–8.
W73. Mele A, Corona R, Tosti ME, Palumbo F, Moiraghi A, Novaco
F, et al. Beauty treatments and risk of parenterally
transmitted hepatitis: results from the hepatitis surveil-
lance system in Italy. Scand J Infect Dis 1995;27:441–4.
W74. Meyer RA, Gordon SC. Epidemiology of hepatitis C virus
infection in a suburban Detroit community. Am J Gastro-
enterol 1991;86:1224–6.
W75. Michault A, Faulques B, Sevadjan B, Troalen D, Marais A,
Barau G. Prevalence of hepatitis A, B, C virus markers in
Reunion (South Hospital and Saint Pierre Prison). Bull Soc
Pathol Exot 2000;93:34–40.
W76. Miller ER, Bi P, Ryan P. Hepatitis C infection in South
Australian prisoners, seroprevalence, seroconversion, and
risk factors. Int J Infect Dis 2009;13:201–8.W77. Mu¨ller Z, Deak J, Horanyi M, Szekeres E, Nagy I, Ozsvar Z,
et al. The detection of hepatitis C virus in South Hungary. J
Clin Virol 2001;20:81–3.
W78. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thompson RA,
Williams AE, et al.; for the NHLBI Retrovirus Epidemiology
Donor Study (REDS*). Risk factors for hepatitis C virus
infection in United States blood donors. Hepatology
2000;31:756–62.
W79. Murray KF, Richardson LP, Morishima C, Owens JW, Gretch
DR. Prevalence of hepatitis C virus infection and risk factors
in an incarcerated juvenile population: a pilot study.
Pediatrics 2003;111:153–7.
W80. Mussi AD, Pereira RA, Silva VD, Martins RM, Souto FJ.
Epidemiological aspects of hepatitis C virus infection
among HIV-infected individuals in Mato Grosso State,
Central Brazil. Acta Trop 2007;104;116–21.
W81. Neal KR, Jones DA, Killey D, James V. Risk factors for
hepatitis C virus infection. A case–control study of blood
donors in the Trent region (UK). Epidemiol Infect 1994;112:
595–601.
W82. Nguyen VT, McLaws ML, Dore GD. Prevalence and risk
factors for hepatitis C infection in rural north Vietnam.
Hepatol Int 2007;1:387–93.
W83. Nishioka SD, Gyorkos TW, Joseph L, Collet JP, MacLean JD.
Tattooing and transfusion-transmitted diseases in Brazil: a
hospital-based cross-sectional matched study. Eur J Epide-
miol 2003;18:441–9.
W84. Nishioka SD, Gyorkos TW, MacLean JD. Tattoos and
transfusion-transmitted disease risk: implications for the
screening of blood donors in Brazil. Braz J Infect Dis
2002;6:172–80.
W85. Nurgalieva ZZ, Hollinger FB, Graham DY, Zhangabylova S,
Zhangabylov A. Epidemiology and transmission of hepatitis
B and C viruses in Kazakhstan. World J Gastroenterol
2007;13:1204–7.
W86. Nyamathi AM, Dixon EL, Wiley D, Christiani A, Lowe A.
Hepatitis C virus infection among homeless men referred
from a community clinic. West J Nurs Res 2006;28:475–8.
W87. O’Brien SF, FanW, Xi G, Yi QL, GoldmanM, FearonMA, et al.
Declining hepatitis C rates in ﬁrst-time blood donors:
insight from surveillance and case–control risk factor
studies. Transfusion 2008;48:902–9.
W88. Pallas J, As-Alvarez CF, Llorca DPJ, Guez MD. Risk factors for
monoinfections and coinfections with HIV, hepatitis B and
hepatitis C viruses in northern Spanish prisoners. Epidemiol
Infect 1999;123:95–102.
W89. Pallas J, As-Alvarez CF, Prieto D, Delgado-Rodriguez M.
Coinfections by HIV, hepatitis B and hepatitis C in
imprisoned injecting drug users. Epidemiol Infect 1999;
15:699–704.
W90. ParanaR,Vitvitski L,AndradeZ,TrepoC,CotrimH,BertillonP,
et al. Acute sporadic non-A, non-B hepatitis in northeastern
Brazil: etiology and natural history. Hepatology 1999;
30:289–93.
W91. Paris R, Sirisopana N, Benenson M, Amphaiphis R,
Tuntichaivanich C, Myint KS, Brown AE. The association
between hepatitis C virus and HIV-1 in preparatory cohorts
for HIV vaccine trials in Thailand. AIDS 2003;17:1363–7.
W92. Patino-Sarcinelli F, Hyman J, Camacho LA, Linhares DB,
Azevedo JG. Prevalence and risk factors for hepatitis C
antibodies in volunteer blood donors in Brazil. Transfusion
1994;3:138–41.
W93. Polizzotto MN, Wood EM, Ingham H, Keller AJ; on behalf of
the Australian Red Cross Blood Service Donor and Product
Safety Team From the Australian Red Cross Blood Service,
Perth, Western Australia, Australia. Reducing the risk of
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940 e939transfusion-transmissible viral infection through blood
donor selection: the Australian experience 2000 through
2006. Transfusion 2008;48:55–63.
W94. Post JJ, Dolan KA,Whybin LR, Carter IW, Haber PS, Lloyd AR.
Acute hepatitis C virus infection in an Australian prison
inmate: tattooing as a possible transmission route. Med J
Aust 2001;174:183–4.
W95. Poulin C, Alary M, Lambert G, Godin G, Landry S, Gagnon H,
et al. Prevalence of HIV and hepatitis C virus infections
among inmates of Quebec provincial prisons. CMAJ
2007;177:252–6.
W96. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N.
Seroprevalence of and risk factors associated with hepatitis
B, hepatitis C, and human immunodeﬁciency virus among
prisoners in Iran. Infect Dis Clin Pract 2007;15:368–72.
W97. Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson
JC, Shubladze N, et al. High prevalence of hepatitis C virus
but not HIV co-infection among patients with tuberculosis
in Georgia. Int J Tuberc Lung Dis 2006;10:396–401.
W98. RobotinMC, Copland J, Tallis G, ColemanD, Giele C, Carter L,
et al. Surveillance for newly acquired hepatitis C in
Australia. J Gastroenterol Hepatol 2004;19:283–8.
W99. Roy E, Haley N, Leclerc P, Boivin JF, Ce´dras L, Vincelette J.
Risk factors for hepatitis C virus infection among street
youths. CMAJ 2001;165:557–60.
W100. Sahajian F, Vanhems P, Bailly F, Fabry J, Trepo C, Sepetjan
M; Members of ADHEC. Screening campaign of hepatitis C
among underprivileged people consulting in health
centres of Lyon area, France. Eur J Public Health
2006;17:263–71.
W101. Salleras L, Bruguera M, Vidal J, Plans P, Dominguez A,
Salleras M, et al. Importance of sexual transmission of
hepatitis C virus in seropositive pregnant women: a case–
control study. J Med Virol 1997;52:164–7.
W102. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Associa-
tion between heroin use, needle sharing and tattoos
received in prison with hepatitis B and C positivity among
street-recruited injecting drug users in New Mexico, USA.
Epidemiol Infect 2001;127:475–84.
W103. Sanchez J, Sjogren MH, Callahan JD, Watts DM, Lucas C,
Abdel-Hamid M, et al. Hepatitis in Peru: risk factors for
infection, potential iatrogenic transmission and genotype
distribution. Am J Trop Med Hyg 2000;63:242–8.
W104. Sandhu J, Preiksaitis JK, Campbell PM, Carriere KC, Hessel
PA. Hepatitis C prevalence and risk factors in the Northern
Alberta dialysis population. Am J Epidemiol 1999;150:
58–66.
W105. Sayad B, Saeed FS, Keyvani H, Rezaii M, Asadi T, Vaziri S,
et al. Seroepidemiology of hepatitis C in Kermanshah (West
of Iran, 2006). Hepatitis Monthly 2008;8:141–6.
W106. Shev S, Hermodsson S, Lindholm A, Malm E, Widell A,
Norkrans G. Risk factor exposure among hepatitis C virus
RNA positive Swedish blood donors—the role of paren-
teral and sexual transmission. Scand J Infect Dis 1995;27:
99–104.
W107. Shi MD, Lee SY, Lee YB. Increased risk of viral hepatitis in
Taiwanese male conscriptees with tattoos. Mil Med
2007;172:539–40.
W108. Shopper T, Boozer C, Lancaster D, Cade JE, Lundgren G.
Presence of anti-hepatitis C virus serummarkers in a dental
school patient population. Oral Surg Oral Med Oral Pathol
1995;79:655–60.
W109. Silverman AL, Sekhon JS, Saginaw SJ, Wiedbrauk D,
Balasubramaniam M, Gordon SC. Tattoo application is not
associated with an increased risk for chronic viral hepatitis.
Am J Gastroenterol 2000;95:1312–5.W110. Stein JA, Nyamathi A. Correlates of hepatitis C virus
infection in homeless men: a latent variable approach.
Drug Alcohol Depend 2004;75:89–95.
W111. Sun CA, Chen HC, Lu SN, Chen CJ, Lu CF, You SL, Lin SH.
Persistent hyperendemicity of hepatitis C virus infection in
Taiwan: the important role of iatrogenic risk factors. J Med
Virol 2001;65:30–4.
W112. Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors
and evaluation of a screening strategy for chronic hepatitis
C and B virus infections in healthy company employees. Eur
J Epidemiol 2001;17:721–8.
W113. Talamini R, Montella M, Crovatto M, Dal Masco L, Crispo A,
Negri E, et al. Non-Hodgkin’s lymphoma and hepatitis C
virus: a case–control study from northern and southern
Italy. Int J Cancer 2004;110:380–5.
W114. Tanwandee T, Piratvisuth T, Phornphutkul K, Mairiang P,
Permpikul P, Poovorawan Y. Risk factors of hepatitis C virus
infection in blood donors in Thailand: a multicenter case–
control study. J Med Assoc Thai 2006;89 (Suppl 5):79–83.
W115. Thaikruea L, Thongsawat S, Maneekarn N, Netski D, Thomas
DL, Nelson KE. Risk factors for hepatitis C virus infection
among blood donors in northern Thailand. Transfusion
2004;44:1433–40.
W116. Thompson SC, Hernberger F, Wale E, Crofts N. Hepatitis C
transmission through tattooing: a case report. Australian
and New Zealand. J Public Health 1996;20:317–8.
W117. Utsumi T, Hashimoto E, Okumura Y, Takayanagi M,
Nishikawa H, Kigawa M, et al. Heterosexual activity as a
risk factor for the transmission of hepatitis C virus. J Med
Virol 1995;46:122–5.
W118. Vaziri S, Mansouri F, Sayad B, Afsharian M, Janbakhsh A,
Karami M. A study of hepatitis D virus infection among HIV
infected patients in Kermanshah, west of Iran. Hepatitis
Monthly 2008;8:252–7.
W119. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S,
Rezza G, Monarca R. Correlates of hepatitis C virus
seropositivity in prison inmates: a meta-analysis. J Epide-
miol Community Health 2008;62:305–13.
W120. Wada K, Greberman SB, Konuma K, Hirai S. HIV and HCV
infection among drug users in Japan. Addiction 1999;94:
1063–70.
W121. Watson R, Crofts N, Mitchell C, Aitken C, Hocking J,
Thompson S. Risk factors for hepatitis C transmission in
the Victorian population: a telephone survey. Aust N Z J
Public Health 1999;23:622–6.
W122. Wolff FH, Fuchs SC, Barcellos NT, Falavigna M, Cohen M,
Branda˜o AB, Fuchs FD. Risk factors for hepatitis C virus
infection in individuals infected with the HIV. Dig Liver Dis
2008;40:460–7.
W123. Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van
Leeuwen DJ. Risk factors for acquisition of hepatitis C virus
infection: a case series and potential implications for
disease surveillance. BMC Infect Dis 2001;1:8.
W124. Zeuzem S, Teuber G, Lee JH, Ru¨ster B, Roth WK. Risk factors
for the transmission of hepatitis C. J Hepatol 1996;24(2
Suppl):3–10.
References
1. Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a
national data set. J Am Acad Dermatol 2006;55:413–21.
2. Deschesnes M, Demers S, Fine`s P. Prevalence and characteristics of body
piercing and tattooing among high school students. Can J Public Health
2006;97:325–9.
3. Health Canada. Special report on youth, piercing, tattooing and hepatitis C trend
scan ﬁndings. Health Canada; 2001. Available at: http://www.phac-aspc.gc.ca/
hepc/pubs/youthpt-jeunessept/pdf/youth_piercings.pdf. (accessed November
12, 2008).
S. Jafari et al. / International Journal of Infectious Diseases 14 (2010) e928–e940e9404. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminat-
ed anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med
1999;340:1228–33.
5. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural
course of hepatitis C virus infection after 22 years in a unique homogenous
cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49:
423–30.
6. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of
targeted look back for HCV infection in the United States—interim results.
Transfusion 2000;40:1176–81.
7. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in
asymptomatic, average-risk adults. Am J Med 2001;111:614–21.
8. Gordon FD. Cost-effectiveness of screening patients for hepatitis C. Am J Med
1999;107:36–40.
9. Hepatitis C quick facts. Public Health Agency of Canada, 2008, Accessed July 19,
2008, http://www.phac-aspc.gc.ca/hepc/index-eng.php.
10. Weild AR, Gill ON, Bennett D, Livingstone SJM, Parry JV, Curry L. Prevalence of
HIV, hepatitis B, and hepatitis C antibodies in prisoners in England andWales: a
national survey. Commun Dis Public Health 2000;3:121–6.
11. Crofts N, Stewart T, Hearne P, Ping XY, Breschkin AM, Locarnini SA. Spread
of bloodborne viruses among Australian prison entrants. BMJ 1995;310:
285–8.
12. Ruiz JD, Molitor F, Sun RK, Mikanda J, Facer M, Colford Jr JM, et al. Prevalence
and correlates of hepatitis C virus infection among inmates entering the
California correctional system. West J Med 1999;170:156–60.
13. Kondro W. Prison tattoo program wasn’t given enough time. CMAJ 2007;176:
307–8.
14. Poulin C, Alary M, Lambert G, Godin G, Landry S, Gagnon H, et al. Prevalence of
HIV and hepatitis C virus infections among inmates of Quebec provincial
prisons. CMAJ 2007;177:252–6.
15. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine
compared with interferon-alpha in the treatment of chronic hepatitis B in the
United States. Am J Manag Care 2001;7:677–82.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA
2000;283:2008–12.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat
Med 2002;21:1539–58.18. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cam-
bridge, Massachusetts: Harvard University Press; 1984.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected
by a simple, graphical test. BMJ 1997;315:629–34.
20. United States Centers for Disease Control and Prevention (CDC). HIV transmis-
sion among male inmates in a state prison system—Georgia, 1992-2005.
MMWR Morb Mortal Wkly Rep 2006; 55:421-6.
21. Khan AJ, Simard EP, Bower WA, Wurtzel HL, Khristova M, Wagner KD, et al.
Ongoing transmission of hepatitis B virus infection among inmates at a state
correctional facility. Am J Public Health 2005;95:1793–9.
22. Ghorpade A. Inoculation (tattoo) leprosy: a report of 31 cases. J Eur Acad
Dermatol Venereol 2003; 16:494–9
23. United States Centers for Disease Control and Prevention (CDC). Methicillin-
resistant Staphylococcus aureus skin infections among tattoo recipients—Ohio,
Kentucky, and Vermont, 2004–2005. MMWR Morb Mortal Wkly Rep 2006;
23:677–9
24. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al.
The prevalence of hepatitis C virus infection in the United States, 1998 through
1994. N Engl J Med 1999;341:556–62.
25. Lanphear BP, Linnemann Jr CC, Cannon CG, DeRonde MM, Pendy L, Kerley LM.
Hepatitis C virus infection in health care workers: risk of exposure and infec-
tion. Infect Control Hosp Epidemiol 1994;15:745–50.
26. Gerberding JL. Incidence and prevalence of human immunodeﬁciency virus,
hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care
personnel at risk for blood exposure: ﬁnal report from a longitudinal study. J
Infect Dis 1994;170:1410–7.
27. Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission
of hepatitis C via blood splash into conjunctiva. (Letter). Scand J Infect Dis
1993;25:270–1.
28. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, et al.
Hepatitis C in hospital employees with needle stick injuries. Ann Intern Med
1991;115:367–9.
29. United States Centers for Disease Control and Prevention (CDC). Provisional
recommendations for hepatitis B vaccination of adults—October 2005. Available
at: http://www.cdc.gov/nip/recs/provisional_recs/hepB_adult.pdf. (accessed Oc-
tober 31, 2006).
30. Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, et al.
Prevalence of HIV and hepatitis C virus infections among inmates of Ontario
remand facilities. CMAJ 2007;177:257–61.
